comparemela.com

Latest Breaking News On - Gang qin - Page 2 : comparemela.com

GeneQuantum and WuXi XDC have entered into strategic cooperation to empower innovative bioconjugates development

/PRNewswire/ GeneQuantum Healthcare (GQ), a global innovative biotechnology company dedicated to the development of the next generation bioconjugate drugs ,.

Gang qinJimmy leeContract researchGenequantum healthcare suzhou co ltdManufacturing organizationQuantum healthcareLigase dependent conjugationWuxi biologicsInvestigational new drugGenequantum healthcare

GeneQuantum Healthcare s Two Next Generation Bioconjugate Drugs, GQ1005 and GQ1007, Have Been Approved for Clinical Trials in Australia

/PRNewswire/ GeneQuantum Healthcare (Suzhou) Co., Ltd. (hereinafter referred to as "GeneQuantum"), a global innovative biotechnology company dedicated to.

Gang qinGenequantum healthcare suzhou co ltdGenequantum healthcareChief executive officerQuantum healthcare

GeneQuantum and AIMEDBIO Collaborate on a First-in-Class Antibody -Drug-Conjugate

/PRNewswire/ GeneQuantum Healthcare (Suzhou) Co., Ltd., a company specializing in site-specific bioconjugation for next generation biotherapeutics, has.

Gang qinDohyun namSamsung medical centerPrnewswire genequantum healthcare suzhou co ltdBio incGenequantum healthcare suzhou co ltdQuantum healthcareAimed bio incAimed bioAntibody drug conjugateLigase dependent conjugationGenequantum healthcare

GeneQuantum announces two key leadership appointments

/PRNewswire/ GeneQuantum Healthcare, an industry-leading biotech company dedicated to the next generation bioconjugate drugs based on the innovative.

United statesGang qinLuye pharmaGenentech incRegulatory affairs departmentUs regulatory affairs certificationQuality researchRutgers universityHead of global regulatory affairsUniversity of notre dameStanford universityRegulatory affairs professional societyQuantum healthcareSenior vice presidentGlobal regulatory affairsWeimeng zhao

GeneQuantum and BrighGene sign agreement for development of antibody immune agonist conjugates

/PRNewswire/ GeneQuantum Healthcare (Suzhou) Co.,Ltd. (hereinafter referred to as "GeneQuantum") and BrighGene Biomedical (Suzhou) Co.,Ltd. (hereinafter.

United statesSouth koreaGang qinEuropean union drug regulatory authorityBrighgene biomedical suzhou co ltdBrighgene biomedical suzhou coPrnewswire genequantum healthcare suzhou co ltdGenequantum healthcare suzhou co ltdQuantum healthcareBrighgene biomedicalPaul songChief scientific officerJiandong yuanChief executive officerGene biomedicalGenequantum healthcare

vimarsana © 2020. All Rights Reserved.